IPP Bureau
.jpg "Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China")
Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China
By IPP Bureau - July 16, 2024
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Merck completes acquisition of EyeBio
By IPP Bureau - July 16, 2024
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
By IPP Bureau - July 16, 2024
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Suven Pharmaceuticals gets Form 483 from with two observations from USFDA for Casper Pharma
By IPP Bureau - July 14, 2024
The company will address these observations within the stipulated timeline
Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
By IPP Bureau - July 14, 2024
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Veerhealth Care secures export order from US Institutional Supplier
By IPP Bureau - July 14, 2024
The company is planning to expand its plant capacity in in Vapi
Thermo Fisher Scientific completes acquisition of proteomics solutions company ‘Olink’
By IPP Bureau - July 14, 2024
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Piramal Pharma’s Ahmedabad facility completes USFDA PAI
By IPP Bureau - July 14, 2024
Health Minister Nadda reviews Ayushman Bharat PMJAY and Ayushman Bharat Digital Mission
By IPP Bureau - July 14, 2024
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
7th India-Japan medical product regulatory symposium held at New Delhi
By IPP Bureau - July 14, 2024
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Moderna and Mitsubishi Tanabe Pharma ink agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan
By IPP Bureau - July 14, 2024
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Lupin receives EIR from USFDA for its Dabhasa facility
By IPP Bureau - July 13, 2024
The facility is a part of Lupin Manufacturing Solutions
KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag
By IPP Bureau - July 10, 2024
KIMS already have a multi-specialty hospital and gastro unit at Vizag
Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
By IPP Bureau - July 10, 2024
The Unit has been issued GMP Certification from ANVISA-Brazil
